Are you eager to deep-dive into Evaxion's business? Download our company presentation.

In this episode of the Big Biz Show, our CEO, Christian Kanstrup, shares the intriguing story of Evaxion and how the company, rooted in machine learning and advanced computational methods, emerged as one of the very few AI-first companies. Since the inception in 2008, Evaxion have developed a unique and strongly validated AI-Immunology™ platform that, as Christian explains it, positions us at the forefront of using AI to discover, design, and develop novel vaccine candidates for cancer and infectious diseases. 

At the LSX - partnering for Life Science eXecutives congress, Director of Immuno-Oncology & Preclinical Development, Stine Friis, shared Evaxion's recent achievements on large pharma deals and the promising data from our Phase 2 personalized cancer vaccine trial, highlighting the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets.

In this episode of the Big Biz Show, our CEO, Christian Kanstrup, delves into the details of the recently announced partnership for vaccine development with MSD, which expands the companies’ existing collaboration and brings significant value to Evaxion.

Advancing Vaccine Development through Precise AI-driven Prediction of Protective Antigens.

CEO Christian Kanstrup joined Steve Darling from Proactive to announce the launch of an enhanced version of the company’s clinically validated AI‑Immunology™ platform, featuring an updated EDEN AI prediction model.

Last week, our CEO, Christian Kanstrup, joined the Life Sciences Investor Forum to present Evaxion's clinically validated AI-Immunology™ platform, highlighting our extensive pipeline of novel vaccine candidates in cancer and infectious diseases and discussing our strategic approach to partnerships.

In this webinar, key opinion leader and the trial’s principal investigator, Professor Georgina V. Long, will present the data from the one-year interim analysis and discuss challenges in the medical treatment of advanced melanoma.

In this interview, Bob "Sully" Sullivan and Mike Costa from the Big Biz Show interview our CEO, Christian Kanstrup, about Evaxion's Innovative AI-Immnuology™ platform, personalized cancer vaccines, and market projections.

Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma